Arvinas and Pfizer’s Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial

Where Today's News Shapes Tomorrow